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This article is a description of the current situation in France with regard to occupational cancer:
research, prevention, and occupation. Toxicologic experiments are carried out using in vitro and in
vivotests, particularly using transgenic mice. Several epidemiologic studies have been conducted
over the last decades: population-based case-control studies; mortality studies and cancer
incidence studies carried out in historical cohorts of workers employed in the industry; and
case-control studies nested in occupational cohorts. French ethical aspects of toxicologic and
epidemiologic studies are described. The results thus obtained are used to establish regulations
for the prevention and the compensation of cancers attributable to occupational exposure. This
French regulation for prevention of occupational cancer involves several partners: a) the states
authorities, including labor inspectors, responsible for preparing and implementing the labor
legislation and for supervising its application, particularly in the fields of occupational health and
safety and working conditions; b) the Social Security Organisation for the analysis of present or
potential occupational risks based on tests, visits in plants, complaints or requests from various
sources, and statistics. These activities are performed within the framework of the general
French policy for the prevention of occupational cancer. This organization includes the National
Institute for Research and Safety, particularly involved in research in the various fields of
occupational risks-animal toxicology, biologic monitoring, exposure measurements
epidemiology, psychology, ergonomy, electronic systems and machineries, exposure to
chemicals, noise, heat, vibration, and lighting; and c) companies where the regulation defines the
role of the plant manager, the occupational physician, and the Health, Safety and Working
Conditions Committee (comprising the manager, employees' representatives, the occupational
physician, and the safety department) in dealing with any problem regarding safety, occupational
hygiene, and working conditions. These organizations along with medical practitioners are
involved with the compensation of occupational cancers. The regulation for compensation
includes the tables of occupational cancer, the possibility of recognition of a cancer case when
the requirements of the tables are not met, and the postprofessional follow-up of workers
exposed to a carcinogenic agent. - Environ Health Perspect 107(Suppl 2):245-252 (1999).
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The rapid worldwide industrialization that
started about a century ago has been accel-
erating over the last decades. This leads to
several technologies, occupations, and pro-
fessions, spreading from industrialized to
developing countries. Therefore, occupa-
tional cancer is one ofthe most important
fields in cancer research and public health
because ofthe numerous practical and the-
oretical implications involving physicians,
biologists, engineers, technicians, economics,
industrials, unions, andsocial partners.
France is concerned about this prob-
lem, as it is one of the oldest and most
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industrialized countries in the world.
Several institutions or organizations are
involved in the various topics resulting
from occupational cancer detection and
prevention including activities such as toxi-
cology, epidemiology, regulation for com-
pensation, and threshold limit values.
Although these topics are not specific to
French working conditions, some of the
methods that deal with these problems
depend on French legislation.
This article is an overview of the
occupational cancer problem in France.
The various topics discussed are a) research
in epidemiology and in animal toxicology,
b) the situation concerning exposures to
known carcinogens, and c) the status of
regulations on occupational exposure to
carcinogens, occupational cancer deserving
compensation, and prevention of occupa-
tional exposure. The roles ofoccupational
physicians and medical practitioners in this
field are also described.
Epidemiologic Studies
O n tion
Epidemiologic studies focused on occu-
pational cancer risks are currently being
conducted in France. The principal inves-
tigators are from several organizations
or institutes in France: the National
Institute for Health and Medical Research
(INSERM), the National Institute for
Research and Safety (INRS), institutes of
occupational medicine from universities, the
Institute for Nuclear Protection and Safety,
cancer registries, and the International
Agency for Research on Cancer (IARC).
Most of these studies are conducted with
the collaboration ofoccupational physicians,
industrial hygienists, medical practitioners,
and other partners, depending on the type
ofstudy.
Most of these studies are performed
following requests from industry, occupa-
tional physicians, unions, the French Social
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Security Organisation, universities, or
IARC. However, some studies specifically
investigate clusters observed by occupa-
tional physicians or medical practitioners.
These studies are case-control studies and
cohort studies.
Case-Contol Studies
This section deals with population-based
case-control studies only (1). Several
independent case-control studies on
occupational risk factors of cancer have
been conducted in France (2). Almost
half these studies have investigated occu-
pational risk factors oflung or other respi-
ratory cancers (2). The other sites of
cancer most frequently studied were can-
cers of the hematopoietic system and
urinary bladder (2).
Sources ofCases. Most oftheses studies
included incident cases ofcancer. The cases
have been identified in hospitals and popu-
lation cancer registries. Hospitals have been
most frequently used as a source of case
identification (public or private hospital,
cancer treatment centers). Several sources
may be used simultaneously as an attempt
to obtain complete coverage of incident
cases covering a given geographical area or
the entire country.
No national cancer registry is available
in France (3). However, well-established
cancer registries cover the population of
about 10 districts (administrative areas),
representing approximately 10% of the
total French population. Some ofthese reg-
istries include only digestive tumors or
hematopoietic cancers (3). For a given
study, the local clinicians and pathologists
who systematically report all cancer cases to
the registry may be asked to report the new
cases of the specific site of cancer to the
study investigator at the time ofdiagnosis.
Some studies have already been conducted
in this way by cancer registries orwith their
collaboration (2). This procedure for
recruiting the cases in population-based
case-control studies may become more
frequent in the future.
Source ofControls. When cases are
recruited among hospitalized patients,
hospital-based controls are also used. The
controls may be other cancer patients or
noncancer patients. The advantages and
the limitations ofthis procedure for select-
ing controls are not specific to France (1).
Controls may be selected among different
groups ofdiagnoses to control for possible
selection biases (1).
No population register is available in
France for epidemiologic studies, but
theoretically other sources may be used to
select general population controls:
* Electoral rolls include all persons of
French nationality, with a high degree
ofcompleteness except in the younger
age groups. As these lists include the
date ofbirth and address ofeach per-
son, they can be used directly for select-
ing controls according to age and to
trace the selected persons. They can be
obtained in each municipality or in the
main city ofeach area.
* Census data are available at the National
Institute for Statistics and Economical
Studies (INSEE). The data consist ofa
list of dwellings, and they cannot be
used to identify the controls with
requested characteristics. The use of
census data implies that the occupants of
the dwelling are contacted to see
whether an eligible control is present.
* Telephone directories can also be used
to identify general population controls.
The telephone coverage is very large in
France, but approximately 20% ofthe
population is not listed in telephone
directories, implying possible selection
biases. Theoretically, this problem
could be solved using a random-digit
dialing procedure, but this method has
rarelybeen used in France.
Data Collection. There are no large
databases in France that include informa-
tion on occupation or on occupational
exposures. However, large job exposure
matrices that would fit to the French con-
text are being elaborated and might be
used more frequently in the future for pop-
ulation-based case-control studies (4).
Questionnaires completed during face-to-
face interviews are the most frequent
method ofdata collection. Although the
early studies addressed cancer risk in rela-
tion to occupational title only, most ofthe
recent studies include detailed data on
occupational history and an evaluation of
different exposures by industrial hygienists
(4). Therefore, detailed occupational expo-
sures could be investigated in the most
recent studies.
CohortSuies
Because there is no cancer registry at the
national level in France (3), most cohort
studies are mortality studies (5,6). Because
of the latency time of cancer, historical
cohorts are usually investigated. Comp-
lementary nested case-control studies are
performed when data on job histories or
smoking habits are not available for all
workers of the study cohorts (1,7). In
addition, some cancer incidence studies
can be conducted in plants located in dis-
tricts having a cancer registry (3). Over
the last two decades, cohort mortality
studies have been conducted in several
industrial sectors-particularly mining,
coal transformation, the steel industry,
metallurgy, and the chemical industry (2).
Individual Data Collection.
Administrative data and job histories
are provided by personnel departments
ofplants.
The vital status ofworkers included in
a historical occupational cohort can be
assessed through a) the administrative reg-
istries of birth places for people born in
France; b) the national file ofthe INSEE,
which provides date and place ofdeath for
people who died in France, regardless of
the place ofbirth; c) the national registry
ofNantes, which contains information on
French people born in a foreign country;
and d) the file ofretired workers that may
exist in some studyplants.
Causes ofdeaths are ascertained from
the national file ofdeath certificates, which
is managed by the INSERM (8). Because
this file was set up in 1968, most follow-up
periods begin in 1968. Before this date,
causes ofdeaths have to be collected from
medical practitioners.
Data on lifestyle such as smoking habits
can be collected from medical records of
each plant for present and pastworkers.
Occupational Exposure Assessment.
Exposure measurements can be performed
by the INRS, the Regional Health
Insurance Funds (CRAMs), or some uni-
versities. They provide information on
current exposure. Past exposure can be
assessed using available past measurements
and through the development of job
exposure matrices specific to the industrial
process ofinterest (9,10).
StatisticalAnalysis. Standard mortal-
ity ratios are calculated as recommended in
the literature (5,6). The reference death
rates are published by the INSERM, at the
national or regional level (95 French dis-
tricts). They provide the numbers ofcauses
of deaths according to sex, 5-year age
groups, and year ofdeath since 1968. Data
from the INSEE provide the correspond-
ing numbers ofsubjects for the calculation
ofdeath rates.
EthlicsinEpideologic S
The conduct ofepidemiologic studies in
France has to meet the requirements ofleg-
islative or regulatory guidelines that are
intended to protect the study subjects
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(11-14). These guidelines cover three
broad areas:
* The automated treatment ofnomina-
tive information (11,12), which deals
with the automated treatment ofnomi-
native information. It is necessary to
obtain the agreement of the Advisory
Committee for the Treatment of
Information and of the National
Commission for Computerizing and
Liberties before the study begins.
* The medical secrecy based on a 2,500-
year-old principle: the respect of the
individual and his privacy. The law on
the treatment ofnominative data (12)
provides for the relaxation of medical
secrecy under certain conditions, partic-
ularly the written consent ofthe indi-
vidual concerned, ifthe information is
to be used for research purposes.
* The laws on the protection ofindividu-
als participating in biomedical research
(13,14), which define the conditions
under which trials, studies, or experi-
ments intended to improve biologic or
medical knowledge can be organized
and carried outwith human beings.
Animal Experimentation
Methods
Although the etiology of human cancer
remains for the most part unknown, many
chemical agents or processes were found to
be carcinogenic in experimental studies or
in epidemiologic research and were classi-
fied as human potential carcinogens (15).
These agents must be induded in consider-
ation of suitable preventive measures, as
well as those agents for which adequate
proof of carcinogenicity in animals exists
without epidemiologic evidence (16). In
vitro or in vivo experimental methods have
been elaborated to address the need for pre-
vention, as the results ofdecisive human
epidemiological studies are often delayed.
From a regulation point ofview, the choice
of tests depends on the quantity of the
chemical agent and ofthe specific effects on
health (17,18). Short-term studies, includ-
ing mutagenesis tests (19), and long-term
carcinogenesis studies (20,21) constitute
the methodologic corpus ofthis assessment.
Mechanistic studies include research on
the understanding of the production and
the target effects offree radicals, the cellu-
lar effects ofproliferation and apoptosis,
the formation of DNA adducts, the direct
or indirect mutagenic effect on DNA, the
change ofgene expression, and the analysis
of the physicochemical properties of
susceptible particle surfaces to explain their
differences in biologic activity.
Only two types oftests can be used in
in vitro carcinogenesis testing (22-25):
the morphologic transformation ofmam-
malian cells in culture (26,27) and the
inhibition ofmetabolic cooperation (28).
Current research works use the survey of
methodologic parameters to improve
their predictiveness.
For in vivo assessment, methods in
molecular biology led to the creation and
use of transgenic animal models from
1984 (29,30). Two types of models have
been developed. First, transgenic models
of mutagenicity permit the identification
and characterization of mutagenic agents
for germ cells and somatic cells. This
model is devoted to measuring mutations
induced by the exposure of a substance
with tissue or organ specificity after an
acute, subchronic, or even chronic expo-
sure. Second, transgenic animal models
for oncogenes or tumor-suppressor genes
have been created to study genetic or epi-
genetic events that occur after an exposure
in conjunction with the mutation to pro-
duce cancer. Still very recent and in con-
stant evolution, these transgenic animal
models open perspectives of mechanistic
understanding and quantification of
target mutations.
In conclusion, characterization of the
potential effects ofcarcinogenic agents is a
major issue in France in terms ofpublic
health and the cost for society. The
research works that permit an understand-
ing of the mechanisms of action of the
chemical agents, fibers, and particles dri-
ving toward a process of carcinogenesis are
therefore important. Such research should
lead to new models, resulting in a reduc-
tion of experimental animal use, a faster,
more reliable detection of potential car-
cinogens, and a better extrapolation to man
of the results of experimental studies in
animals. This last point will permit a more
accurate assessment of the implications of
the exposure to carcinogenetic agents for
human health.
EticalAspect
Before entering production, any new
chemical product must undergo a series of
toxicologic tests, particularly tests to verify
whether the substance is a potential car-
cinogen. In vitro experiments cannot
involve the entire set ofbiologic phenom-
ena, and it would be unethical to extend
the results to humans without examining
in vivo models. As a consequence and
because such experiments are irreplaceable
(31), it is our responsibility to respect the
animal subjects and consider their capaci-
ties for suffering and remembering. The
ethical principles imposed by current legis-
lation are based on the "three Rs" of
Russel and Burch (32): replace, reduce,
and refine (33-35).
French legislation is designed to con-
form to the European and French texts on
this issue, particularly with Council
Directive no. 86/609/EEC of24/11/1986
(36) and the French Decree no. 87-848 of
19/10/1987 (37,38).
Currently there are no regulatory texts
on the creation ofethics committees because
the system chosen by France is based on an
authorization delivered to responsible and
competent individuals (conforming to
article 7-1 of the Council Directive no.
86/609/EEC) (32). Because ofthe applica-
tion ofthis set ofdirectives, the number of
animals used in experiments has decreased
25% over the last 10 years without causing a
reduction in research activity (39,40).
Exposure to Some
Carcinogens ofthe
IARC Classification
Eposure toFibers,Silica,
andWoodDust
Fibers. ASBESTOS. Individualization of
asbestos-related disease has been made since
1975. Specific preventive rules concerning
asbestos have been promulgated since 1976,
with progressive interdiction of materials
containing asbestos, and elaboration of
health and safety procedures in order to
control exposure. All regulations were in
agreement with directives from the
European Union. Exposed workers are
included in a special medical survey con-
ducted during and after exposure and based
on biannual chest X-ray and spirometry. As
in other countries, however, those rules have
been difflcult to apply in small plants and
among end users. A complete banishment
(with an exception list) of new manufac-
tured products containing asbestos was
applied in France in 1997. However, expo-
sure resulting from in-place asbestos will still
be a major problem for some decades. New
threshold limit values were proposed for
1997: 0.1 fibers/ml/hr. A recent analysis of
the French situation was conducted at the
request ofour national health research insti-
tute, INSERM. It was estimated that, in
1996, more than 700 patients with
mesothelioma and 1250 patients with lung
cancer related to occupational exposure
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would die (41). Those figures represent the
consequences of exposure before 1976
because ofthe longlatencyperiod ofrespira-
tory cancers. During 1995, only 554 new
cases ofall asbestos-related diseases were
compensated, including 171 asbestos, 272
nonmalignant pleural diseases, 77 mesothe-
lioma (mainly pleural), and 21 lung cancers
(42). But it was not possible to predict the
expected number of cases resulting from
more recent exposure because ofinsufficient
data on the number ofexposed subjects and
the levels ofexposure in the last 20 years. It
is estimated that between 1 and 10% of
active workers have been exposed, at least
occasionally, during the last 20 years.
Figures such as those presented by Peto et al.
(43) for England are also possible. The
French cancer registries have estimated an
increasing incidence of mesothelioma of
25% each 3 years from 1985 to 1995 (44).
This is in accordance with the French ongo-
ing multicenter mesothelioma case-control
study, inwhich more than 70% ofcases had
occupational asbestos exposures, essentially
among end users such as those in building
industries (4,45).
OTHER FIBERS. Mineral and synthetic
fibers, especially mineral wools, are also
widely used in France. Most ofthe data on
fibers have been obtained in experimental
models, either in chronic oncogenic experi-
ments or in biopersistence in vivo experi-
ments. International meetings have
recently presented new data that suggest
that fine and long biopersistent fibers such
as ceramic fibers were associated with a sig-
nificant risk ofmesothelioma, fibrosis, and
lung cancer in rodents. Moreover, those
data are of utmost importance in produc-
ing new fibers with fewer potential biologic
effects. No specific data are available for
France, as French plants were not involved
in the European follow-up until recently.
Since 1995, the French Ministry ofLabour
has recommended a threshold limit value
of 1.5 f/ml (1 fiber in 1997) for mineral
wools and 1 f/ml (0.6 f/ml in 1997) for
ceramic fibers.
Silica. Silica exposure in the occupa-
tional environment is extremely frequent
(46). Mines and quarries are exposed work-
places that employed nearly halfa million
persons in France after War World II.
Today this population is restricted to less
than 30,000 workers. Specific health and
safety regulations are involved in this sector,
including a threshold limit value for occupa-
tional exposure to free silica at 0.25 mg/m3
for a pure crystalline silica aerosol. A special
medical survey is conducted during and
after the period ofactivity, based on chest
X-ray (lecture according to International
Labour Organisation classification) and
spirometry. Silicosis is an occupational dis-
ease that can include some nonmalignant
complications. Lung cancer occurring
within a silicosis is not presently compen-
sated. In 1994, 28,000 workers still alive
were compensated, with only 331 new cases
for 1994. Iron mines workers had only 438
workers compensated in 1994. Siderosis is
also compensated with more than 1,000
prevalent cases and 36 new cases in 1994
(47). Lung cancer can be compensated as a
complication ofsiderosis in France.
Apart from extractive industries, silica
exposure is frequent, mainly in building
industries that include tunneling, ceramic
production, abrasive production, and glass
manufacture. It is possible to give a precise
number ofworkers involved based on iden-
tification by occupational physicians ofsub-
jects included in the special silica medical
survey. Probably more than 1% ofactive
workers are involved. Organization ofpre-
ventive strategies is slightly different from
that ofextractive industries, with a thresh-
old limit value of 0.1 mg/m3 for quartz.
The medical survey is also based on annual
chestX-ray and spirometry during and after
exposure. The main sample ofcompensa-
tion exists as in extraction industries; in
1993, 226 new cases ofsilicosis were com-
pensated. There was a significant decrease
from the 1980s (around 600 cases), but val-
ues have been stable since 1988 (42). This
must be considered in the evaluation ofa
potential carcinogen risk.
Wood Dusts. Sinonasal cancers are
well related to occupational exposure to
wood dust, as recently reported in an
important case-control study conducted
in France from 1986 to 1988 (48). It was
reported that risk was higher for hard
wood and adenocarcinoma; all but 2 of
the 82 male cases with adenocarcinoma
were exposed. A 2-fold increase in riskwas
observed for squamous cell carcinoma.
Moreover, another analysis of the same
population has suggested an interaction
with other chemicals such as formalde-
hyde, glues, and adhesives. As exposure to
all those products is highly correlated, the
exact model ofthis interaction could not
be correctly described (49).
However, it is still difficult to assess
precisely the number ofexposed workers.
Cases of sinonasal cancer among wood-
workers are compensated as occupational
diseases and the number of compensated
cases during the past decade ranged
between 20 and 40 each year (42). Finally,
recommendations were proposed to limit
exposure to less than 3 mg/m3 ofinhalable
dusts in 1993 and less than 1 mg/m3 in
1997. Obligatory integration ofventila-
tion/aspiration systems within the tool
machines will certainly greatly contribute
to reducing the level ofexposure.
Expsure toMetals ListedbyIARC
In France, the reference to IARC lists of
carcinogens, in terms of metals and com-
pounds and workplace regulations, is miti-
gated by the fundamental European
Directive 90/394/EEC on Carcinogens at
the Workplace, defining carcinogens
through European Directive 67/548/EEC
and its annex I (50,51). The latter is a list
of precisely defined carcinogenic sub-
stances [carcinogens category 1 (proven for
humans) and category 2 (probable for
humans)]. This leads to a significant dif-
ference between IARC and EEC lists
through the introduction ofthe speciation
concept. IARC lists (15) in its overall
evaluation a metal and its compounds,
whereas European Directive 67/548 lists
some precise metal compounds and possi-
bly the metal itself (51). All metals and
compounds listed as carcinogens are
indeed carcinogenic, most ofthem only by
inhalation. (Risk phrase R 49 is "may
cause cancerbyinhalation.")
Prevention ofoccupational cancers in
relation to metals and related compounds
must take into consideration the unique
characteristic that metals, as elements, are
ubiquitous in the workplace atmosphere or
ambient air and can be quantified as a
background exposure. This leads to the
question in the course ofthe regulatory risk
assessment process ofthe definition ofa de
minimis level, or action level above which
the prevention should reallyapply.
In addition to designation ofa metal or
some of its compounds as carcinogenic at
the workplace, certain processes can be also
dassified/designated as potentially carcino-
genic for humans. This is the case ofsome
nickel-refining steps (listed as such in
Annex I to European Directive 90/394)
(50) or aluminium production, under-
ground hematite mining with exposure to
radon, or iron and steel founding, where
sometimes the quoted metal is not directly
concerned as the causal agent. For instance,
in the case ofaluminium production and
iron and steel founding, the causal agents
are polyaromatic hydrocarbons.
Another characteristic of metals in
terms ofpossible carcinogenicity is that
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often, ifnot in most ofthe situations, they
are present at the workplace in a nondis-
persible form (i.e., massive form) thatelimi-
nates naturally all possibilities ofsignificant
exposures byinhalation.
Some O tion-Related Cancer
intheChemical Industry
The prevention of occupation-related
cancers in the chemical industry is based
essentially on the principles outlined in
European Directive 90/394/EEC (50).
The evaluation of the real danger is the
key element to this approach, a strategy
founded on well-understood methods used
in industrial health and safety:
* Hazard evaluation, i.e., the presence of
either carcinogens as defined inAnnex 1
ofthe EEC Directive 67/548/EEC (51)
(categories 1 and 2) or intermediates
(short duration) used in a fabrication
process and defined as being carcino-
genicaccording to the same criteria;
* Risk evaluation, i.e., demonstrating the
possibility ofexposure to carcinogens.
This evaluation is based on a study of
the process in question and anypossible
contacts with such substances, includ-
ing measurements oftheir atmospheric
concentrations and biologic monitoring
when possible (i.e., when the measure-
ment ofa compound or one ofits rep-
resentative metabolites can be
performed with sufficient specificity
and sensitivity); and
* Risk management, i.e., after an initial
analysis at the workplace, a sampling
strategy is developed using a study of
the probability ofexceeding the refer-
ence values (either published limit val-
ues orvalues specific to the enterprise at
hand when no published limits are
available). In the case ofsubstances still
in a preindustrial research/development
stage, it is necessary to use a strategy
that uses confinement grading tech-
niques. These techniques are based on
the results ofa rapid toxicologic screen-
ing test using alternative methods, on
the foreseeable duration and intensity
of the exposure, and on the physical
and chemical properties ofthe chemical
involved. Medical and biologic moni-
toring (search for reversible adverse
effects) are conducted simultaneously.
Risk evaluation and risk management are
both supported by information from
workers and managers. Their active coop-
eration is always encouraged because an
efficient prevention system needs the
participation of the actors (i.e., involved
people). Some examples may illustrate this
prevention in the field ofrisk assessment,
risk management, and health surveillance.
* Benzene: occupational exposure to ben-
zene is regulated using blood cell
counts. In earlier prevention efforts,
nonmandatory biologic monitoringwas
developed in cooperation with the
INRS, with trans-trans-muconic acid in
urine as provisional biomonitoring.
* Aromatic amines: the French regulation
includes nonspecific research of free
amines in urine by colorimetric method;
dosage oftransaminases (alanine-amino
transferase and aspartate- amino trans-
ferase) for suspected hepatotoxic sub-
stances; and cytologic examination and
research ofblood in urine.
With the accuracy ofanalytic methods
and on a voluntary basis, we promote
identification and dosage ofthe amine
itself and its identified metabolites as
early indicators ofexposure, especially
in the case ofskin penetration.
* Vinyl chloride: existing regulation is
based on an exposure limit in the work-
place. This evaluation is completed
with a clinical surveillance twice a year.
From a consensus conference, transami-
nases, alkaline phosphates, blood cell
count (once a year), and hepatic vessels
echography (every 2 years) were added.
In a prospective study, carcinogenic
biomarkers are being investigated.
* Bischloromethylether: based on air
monitoring, this surveillance is com-
pleted by some occupational physicians
who have developed lung cell micro-
scopic studies.
Prevention ofOccupational
Cancer
The rnchFramework
Following the historical development ofthe
French legislation, several organizations are
involved in the prevention ofoccupational
cancer, including state authorities, the
Social Security Organisation, companies,
and trade or private organizations.
State Authorities. The Labour
Ministry prepares and implements the
labor legislation, and supervises its appli-
cation, particularly in the fields ofoccupa-
tional health and safety and working
conditions. In so doing, the main activi-
ties of this ministry are a) to prepare the
work of the Superior Council for the
Prevention ofOccupational Risks to draw
up regulations and to develop preventive
policies; b) to supervise the National
Agency for the Improvement ofWorking
Conditions, to help companies, trade
organizations trade unions, and educa-
tional organizations improve working
conditions. Consequently, this agency is
involved in collecting and providing rele-
vant information, producing guides and
analytic and teaching aids, and undertak-
ing or sponsoring studies or pilot projects;
and c) coordinating and promoting the
activities ofthe Labour Inspectorate. The
labor inspectors are responsible for enforc-
ing the relevant legislation and regula-
tions. They perform investigations
following serious accidents. They also
provide information and advice to
employers and employees. In addition,
the labor inspectors must work with the
labor medical inspectors to ensure that the
legislation relating to occupational
hygiene and health protection at work is
properly observed, and to supervise the
activities ofoccupational physicians.
The SocialSecurity Organisation The
Social Security Organisation includes the
National Health Insurance Fund for
SalariedWorkers (CNAMTS), the CRAMs,
and the INRS (52,53).
The activities of the CRAMs involve
analysis of present or potential occupa-
tional risks based on visits, tests, com-
plaints, or requests from various sources,
and statistics. These activities are per-
formed within the framework ofthe gen-
eral prevention policy developed in
conjunction with the CNAMTS.
The INRS is involved in research in the
various fields ofoccupational risks (animal
toxicology, biologic monitoring, exposure
measurements, epidemiology, psychology,
ergonomy, physiology, electronic systems
and machineries, and exposure to chemi-
cals, noise, heat, vibration, lighting), and
training, information and assistance to
CRAMs, occupational physicians, and the
Health, Safety and Working Conditions
Committee (CHSCT).
This organization also includes the
National Technical Committees and the
Regional Technical Committees (man-
agers and employers, representatives).
These committees are specific to different
economic sectors.
Companies. The plant manager has the
authority and resources to determine work
procedures and to choose equipment that
ensures safety in the workplace. He may be
assisted by asafetydepartment.
The occupational physician is in
charge of clinical examinations for work-
ers and advising the manager, employees,
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and their representatives on any problem
relating to occupational hygiene and
working conditions.
The main organization involving
employees in the management ofpreven-
tion is the CHSCT in factories having
more than 50 employees. This committee
is chaired by the manager and comprises
employee representatives, the occupational
physician, and the safetydepartment.
Trade or Private Organizations.
Organizations specific to certain economic
sectors provide relevant information or
technical advice on the prevention of
occupational risk and perform regular
measurements on exposure in workplaces
(e.g., chemical exposure, noise, lighting).
General Res
Specific Provisions. Following the
European Directive 90/394/EEC (50) of
June 1990, Decree no. 92-1261 (54) con-
cerning the prevention of chemical haz-
ards, specific provisions were included in
the French Labour Code on the preven-
tion of occupational cancer risks. These
provisions apply to all substances or
preparations defined as carcinogenic cate-
gory 1 (proven for humans) and category
2 (probable for humans) through the
European Directive 67/548/EEC and its
annex I (50,51). Such products shall be
labeled carcinogens. In addition, a gov-
ernment order defined the following
processes as producing carcinogenic
agents: manufacture of auramine; work
involving exposure to polycyclic aromatic
hydrocarbons present in coal soot, tar,
pitch, fumes, or dust; work involving
exposure to dusts, fumes, and sprays pro-
duced during the roasting and electro-
refining of cupro-nickel mattes; and the
strong acid process in the manufacture of
isopropyl alcohol.
In all plants where such products or
processes are used, Decree no. 92-1261
(54) requires the employer to implement
technical and medical prevention meas-
ures and to provide adequate information
and training.
Technical Measures. In addition to
specific provisions, technical measures
must be applied: a) the employer shall
regularly assess the nature, level, and
duration ofexposure, taking all exposure
routes (inhalation, ingestion, percuta-
neous penetration) into account; b) the
employer shall reduce to a minimum the
use of carcinogenic agents, in particular
by replacing them with less dangerous
products or processes; c) the employer
shall reduce to a minimum the duration
of exposure and the number of exposed
workers; and d) the employer shall provide
the necessary protective equipment and
keep it in good condition.
Medical Examination. Before being
employed in a workplace where exposure
to carcinogens is likely to occur, each
worker must undergo an ad hoc medical
examination by the occupational physi-
cian of the plant. This examination shall
be performed every 6 months. For each
worker, a medical record shall be set up
and archived, indicating a description of
the work, the duration of exposure, and
the results of clinical and biologic exami-
nations. This record is to be archived for
at least 40 years after the end ofexposure.
If the worker moves to another company,
the medical record relating to occupa-
tional exposure is transmitted to the
occupational physician.
Training and Information. The
employer shall organize appropriate safety
training for workers exposed to cancer risks
with the advice ofoccupational physicians
and CHSCT. The employer shall also
inform the workers, the occupational physi-
cian, the members ofthe CHSCT, and the
competent health and safety inspectors of
the hazards associated with the products
used, the work organization, the incidents
that have occurred, and the safety measures
that have been implemented. In particular,
the employer shall ensure that all products
are adequately labeled.
Restriction andProhibition ofUse.
Decree no. 89-593 (55) following
European Directive 88/364/EEC (56)
prohibited the production and use (except
for research, scientific analysis, or disposal
purposes) ofpreparations containing more
than 0.1 % (weight percentage) of four
carcinogenic substances (55).
Other provisions prohibit the
appointment of different categories of
workers (workers under a fixed-term con-
tract of employment, temporary workers,
young workers) for certain jobs (e.g.,
asbestos work).
When workers have to carry out tasks
on the premises ofanother company and
when those tasks involve possible exposure
to carcinogenic agents, both employers
must jointly draw up a written prevention
plan beforeworkstarts.
Special Regulation Applicable to
Certain Prodcts. This concerns the use of
X-rays, arsenic, benzene, asbestos, vinyl chlo-
ride, and ionizing radiations. All such prod-
ucts require particular technical measures,
work organization measures, ambient air
monitoring, medical surveillance, training,
and information.
Compensation for
Occupational Cancer
One of the aims of the Social Security
system set up in 1945 was to protect
employees and their families against all
risks likely to impair or deprive them of
their abilities at work. Thereafter, com-
pensation for industrial accidents and
occupational diseases became a part ofthe
system (57). The Social Security funds
are responsible for the management of
industrial accidents and occupational dis-
eases. Furthermore, the employers are
responsible for financing these damages
through a tariffsystem using contribution
rates varying according to the number and
seriousness ofaccidents or diseases.
Methods forIdentfyingOccupational
Cancers
The primary method used to identify
occupational cancers is the procedure in
the Tables of Occupational Diseases
(Tableaux de Maladies Professionnelles)
(58-60). A patient with cancer can be
identified and compensated for occupa-
tional disease if the following conditions
are fulfilled:
* The disease is formally listed in the
table.
* The subject has participated in one of
the occupational activities mentioned
in the table. (The lists ofactivities given
in tables may not be exhaustive.)
* There is a delay in compensation, i.e.,
time elapsed between the end of the
exposure ofinterest and the date ofthe
diagnosis of the disease. (This delay
can be up to 50 years for certain types
ofcancer.)
Any French physician, occupational
physician, or medical practitioner, with the
agreement of the patient, has to report
cancer cases that meet these requirements.
An additional procedure is planned for
the recognition of cancer cases when all
requirements ofthe table are not met com-
pletely, through the expertise of the
Regional Committee for the Recognition
ofOccupational Diseases (61).
Postprofssional Foliow-Up
In addition to these regulations, the post-
professional follow-up procedure was set
up in 1993 (54). This consists of health
surveillance ofworkers after their occupa-
tional exposures to carcinogenic risk or
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processes (61). This follow-up is made by
physicians, occupational physicians, or
medical practitioners for all workers who
provide a certificate of exposure written
by the manager and the occupational
physician ofthe activity ofinterest.
Ocpationl Cancs Deserving
Compensation
The tables concerning lung cancer are
related to exposure to asbestos, arsenic
dusts and vapors, bischloromethylether,
coal tars and oils, coal tar pitch, soot,
chromic acid, chromates, roasting ofnickel
matte, ionizing radiation, and iron oxide
dust in iron ore mining (lung cancer with
siderosis) (58-60).
The tables concerning other cancer are
(58-60) bladder (exposure to N-nitroso-
butylamine, aromatic amines, coal tars and
oils, coal tar pitch, and soot), nose and
sinuses (exposure to wood dust and to
roasting ofnickel matte), pleural mesothe-
lioma (exposure to asbestos), leukemia
(exposure to ionizing radiation and ben-
zene exposure), sarcoma (exposure to ioniz-
ing radiation), angiosarcoma of the liver
(exposure to vinyl chloride), and skin
(exposure to coal tars and oils, coal tar
pitch, soot, and mineral oils).
NumberofCompensatd
cer C
Despite the great number of the above-
mentioned occupational cancer tables, the
number ofcompensated cases remains low
compared to the size ofthe French popu-
lation. The number of compensated
cancer cases has been rising from about 50
compensated cases peryear in the 1970s to
about 150 to 200 cases during the 1990s
(62,63). About 50% ofcompensated cases
in the 1990s are due to asbestos (84
mesothelioma and 33 lung cancer in
1994) (64). According to the published
estimates suggesting that about 4% ofall
cancer cases could be attributable to occu-
pational exposure (65), the number of
occupational cancer cases deserving com-
pensation would be approximately 7,000
each year in France (62,63).
This suggests an underestimation of
cancer cases attributable to occupational
exposures. Several factors may be responsi-
ble for this underestimation: a) the relative
importance oflifestyle and occupational
factors is difficult to assess at an individual
level (e.g., smoking and occupation for lung
cancer), b) interactions between occupa-
tional factors, c) time elapsed between first
exposure and cancer diagnosis, d) past
exposure difficult to assess, mainly because
ofindustrial processes no longer performed,
and e) lack ofknowledge by medical practi-
tioners on occupational exposure for
diagnoses after retirement.
Roles ofOccupational
Physicians and Medical
Practitioners
Occupational physicians and medical
practitioners have important roles in both
prevention and compensation of occupa-
tional cancer. Although detailed descrip-
tions are given in previous sections ofthis
article, some activities of occupational
physicians and medical practitioners must
be emphasized:
* The occupational physician is the
manager's adviser. He contributes to
the assessment ofthe carcinogenic haz-
ards in the company (15) and to the
research for alternative noncarcino-
genic products or processes. When a
carcinogenic agent has to be used, he
provides advice to decrease the number
of exposed workers, exposure levels,
and duration.
* The occupational physician is involved
in providing information and training
to workers about cancer prevention,
with emphasis on the efficiency ofcol-
lective protection as opposed to indi-
vidual protection; the synergy between
occupational and nonoccupational car-
cinogens (e.g., smoking and asbestos
exposure); and the selection, appropri-
ate use, and maintenance ofpersonal
protective equipment.
* Regarding compensation, the occupa-
tional physician has a role for the detec-
tion ofoccupational cancer that may
occur after retirement. First, he has to
draw up the certificate ofexposure with
the manager. Second, he has to supply
the future retiree with relevant advice
and data that could be useful for the
medical practitioner who will follow
him after theworker retires.
* Thus, the medical practitioner will use
this information for the surveillance of
such workers.
In addition, regarding research and the
detection of new risks of occupational
cancer, occupational physicians and med-
ical practitioners may observe similar
cancer diagnoses, during short periods of
time, that could be considered clusters.
Such results could generate hypotheses for
further formal epidemiologic and toxico-
logic studies that may detect occupational
cancer risk.
REFERENCES AND NOTES
1. Breslow NE, Day NE. Statistical Methods in
Cancer Research. Vol l: The Analysis of
Case-Control Studies. Sci Publ No 32.
Lyon:lnternational Agency for Research on
Cancer, 1980.
2. Aubrun JC, Binet S, Bozec C, Brochard P,
Dimerman S, Fontaine B, Guenel P, Luce D,
Martinet Y, Moulin JJ, et al. les cancers pro-
fessionnels en France. Situation actuelle pour
la recherche, la prevention et la reparation.
Cahiers de Notes Documentaires INRS
169:533-545 (1997).
3. Koscielny S, Rezvani A, Laplanche A, Esteve J,
Ferlay J. Estimation de l'indicence des cancers
en France-1983-1987. Paris:Les Editions
INSERM, 1996.
4. lwatsubo Y, Pairon JC, Boutin C, Menard 0,
Massin N, Caillaud D, Orlowski E, Galateau-
Salle F, Bibnon J, Brochard P. Pleural mesothe-
lioma: dose-response relation at low levels of
asbestos exposure in a French population-
based case-control study. Am J Epidemiol
148:133-142 (1998).
5. Breslow NE, Day NE. Statistical Methods in
Cancer Research, Vol Il: The Design and
Analysis of Cohort Studies. Sci Publ No 82.
Lyon:lnternational Agency for Research on
Cancer, 1987).
6. Coleman M, Douglas A, Hermon C, Peto J.
Cohort study analysis with a Fortran computer
program. IntJ Epidemiol 15:134-137 (1986).
7. Moulin JJ, Wild P, Romazini S, Lasfargues G,
PeltierA, Bozec C, DeguerryP, Pellet F, PerdrixA.
lung cancer risk in hard-metal workers. Am J
Epidemiol 148:241-248 (1998).
8. Decret N° 98-37 du 16 Janvier 1998 autorisant
l'acces aux donnees relatives aux deces des
personnes inscrites au Repertoire National
d'Identification des Personnes Physiques dans
le cadre des recherches dans le domaine de la
sante. J.O. 18 Janvier 1998.
9. Goldberg M, Leclerc A, Chastang JF, Goldberg
P, Brodeur JM, Fuhrer R, Segnan N. Evaluation
retrospective d'expositions professionnelles
dans les etudes 6pidemiologiques. Utilisation
de la methode Delphi. Rev Epidem et Sant6
Publ 34:245-251 (1986).
10. Moulin JJ, Romazini S, Lasfargues G, Peltier A,
Bozec C, Deguerry P, Pellet F, Wild P, Perdrix A.
Elaboration d'une matrice emplois-expositions
dans lindustrie productrice de metaux durs en
France. Rev Epidem et Sante Publ 45:41-51
(1997).
11. Loi no 78-17 du 6 Janvier 1978 mod. relative a
l'informatique, aux fichiers et aux libertes. J.O.
7 Janvier 1978(rectificatifJ.O. 25Janvier 1978).
12. Loi n° 94-548 du ler Juillet 1994 relative aux
traitements de donnees nominatives ayant pour
fin la recherche dans le domaine de la sante et
modifiant la loi n° 78-17. J.O. du 6 Janvier 1978
relative a linformatique, aux fichiers et aux lib-
ertes. J.O. 2Juillet 1994.
13. Loi n° 88-1138 du 20 Decembre 1988 relative a la
protection des personnes qui se pretent a des
recherchesbiomedicales.J.O. 22 Decembre 1988.
14. Loi no 94-630 du 25 Juillet 1994 modifiant le
livre lIbis du code de la sante publique relatif a
la protection des personnes qui se pretent a des
recherches biomedicales. J.O. 26 Juillet 1994.
Environmental Health Perspectives a Vol 107, Supplement 2 * May 1999 251AUBRUN ETAL.
15. IARC. IARC Monographs on the Evaluation of
Carcinogenic Risks to Humans: Preamble and
Lists of IARC Evaluations. Lyon:lnternational
Agency for Research on Cancer, 1993.
16. Hygiene & securite, J. Pluyette. 21e ddition.
Paris:Technique et Documentation, 1994,
1654-1659.
17. Directive 92/32/CEE du conseil du 30 avril 1992
portant 7e modification de la Directive
67/548/CEE concernant le rapprochement des
dispositions legislatives, reglementaires et
administratives relatives a Ia classification,
l'emballage et l'etiquetage des substances
dangereuses. J.D.C.E. n° L 154, 5Juin 1992.
18. Arrete du 20 avril 1994 mod. relatif a la decla-
ration, la classification, Iemballage et lIetique-
tage des substances. J.D. 8 Mai 1994.
19. Kilbey BJ, Legator M, Nichols W, Ramel C.
Handbook of Mutagenicity Test Procedures.
2nd ed. Amsterdam:Elsevier Scientific Publ, 1985.
20. OCDE. Etudes de cancerogenbse. Ligne direc-
trice de I'OCDE pour les essais de produits
chimiques n° 451, adoptee le 12 mai 1981.
21. IARC. Long-term and Short-term Screening
Assays for Carcinogens: A Critical Appraisal.
IARC Monographs. Suppl 2. Lyon:lnternational
Agency for Research on Cancer, 1980.
22. Ashby J, Tennant RW. Definitive relationships
among chemical structure, carcinogenicity and
mutagenicity for 301 chemicals tested by the
U.S. NTP. Mutat Res 257:29-306 (1991).
23. International Seminar on Assessment of
Carcinogenic Risk from Occupational Exposure
to Inorganic Substances. 17-20 October 1995.
Luxembourg.
24. Hesterberg TW, Oshimura M, Brody AR, Barrett
JC. Asbestos and silica induce morphological
transformation of mammalian cells in culture: a
possible mechanism. In: Silica, Silicosis and
Cancer: Controversy in Occupational Medicine
(Goldsmith DF, Winn DM, Shy CM, eds). New
York:Praeger, 1986;177-190.
25. Elias Z, Poirot 0, Schneider D, Marande AM,
Danimre MC, Terzetti F, Pezerat H, Fournier J,
Zalma R. Cytotoxic and transforming effects of
some iron-containing minerals in Syrian hamster
embryo cells. Cancer Detect Prev 5:405-414
(1995).
26. Dhalluin S, Elias Z, Cruciani V, Bessi H, Poirot 0,
Rast C, Gate L, Pages N, Tapiero H, Vasseur P,
et al. Two-stage exposure of Syrian-hamster-
embryo cells to environmental carcinogens:
superinduction of ornithine decarboxylase corre-
lates with increase of morphological-transforma-
tion frequency. IntJ Cancer 75:744-749 (1998).
27. Jones CA, Huberman E, Callaham MF, Tu A,
Halloween W, Pallota S, Sivak A, Lubet RA,
Avery MD, Kouri RE, et al. An interlaboratory
evaluation of the Syrian hamster embryo cell
transformation assay using eighteen coded
chemicals. Toxicol in Vitro2:103-116 (1998).
28. Trosko JE, Chang CC. Nongenotoxic mecha-
nisms in carcinogenesis: role of inhibited inter-
cellular communication. In: Carcinogen Risk
Assessment: New Directions in the Qualitative
and Quantitative Aspects. Banbury Report 31.
(Hart RW, Hoerger FD, eds). Cold Spring Harbor,
NY:Cold Spring Harbor Laboratory Press, 1998:
139-170.
29. Goldsworthy TL, Recio L, Brown K, Donehower
LA, Mirsalis JC, Tennant RW, Purchase IFH.
Symposium Overview: Transgenic Animals in
Toxicology. Fundam AppI Toxicol 22:8-19(1994).
30. Mirsalis JC, Monforte JA, Winegar RA.
Transgenic animal models for detection of in vivo
mutations. Annu RevToxicol 35:145-164(1995).
31. INSERM. Livre Blanc sur l'Experimentation
Animale. Paris:CNRS Editions, Les Editions
INSERM, 1995.
32. Russel WMS, Burch RL. Principles of Humane
Experimental Technique. Bethesda, MD:Charles
C. Thomas, 1959.
33. Balls M. Replacement of animals procedures:
alternatives in research, education and testing.
Lab Animals 28:193-211 (1994).
34. Festing MFW. Reduction of animal use: experi-
mental design and quality of experiments. Lab
Animals 28:212-221 (1994).
35. Flecknell PA. Refinement of animl use-
assessment and alleviation of pain and dis-
tress. Lab Animals 28:222-231 (1994).
36. Directive du Conseil n° 86/609/CEE du 24
Novembre 1986, concernant le rapprochement
des dispositions legislatives, reglementaires et
administratives des Etats membres relatives a
la protection des animaux utilises a des fins
experimentales ou a d'autres fins scientifiques.
J.O. n° L 358, 18 Decembre 1986.
37. Decret N° 87-848 du 19 Octobre 1987 pris pour
l'application de l'article 454 du code penal et
du troisieme alinea de l'article 276 du code
rural et relatif aux experiences pratiquees sur
les animaux. J.O. 20 Octobre 1987.
38. Arrete du 19 Avril 1988 fixant les conditions
d'agrement, d'amenagement et de fonction-
nement des etablissements d'experimentation
animale. J.O. 27 Avril 1988.
39. Erb HN. A statistical approach for calculating
the minimum number of animals needed in
research. liar News 32:11-16 (1990).
40. Feinberg M. Optimisation de la Reponse. In: La
Validation des Methodes d'Analyse.
Paris:Masson Editeur, 1996;251-271.
41. INSERM. Rapport sur les effets sur la sante de
l'amiante. Expertise collective. Paris:B. Tonnel,
President, Paris. Paris:Les Editions de l'INSERM,
1996.
42. CNAMTS. Statistiques Financieres et
Technologiques des Accidents du Travail
(1991-1993). Paris, 1995.
43. Peto J, Hodgson JT, Matthews FE, Jones JR.
Continuing increase in mesothelioma mortality
in Britain. Lancet 345:535-539 (1995).
44. Menegoz F, Grosclaude P, Arveux P, Henry-
Amar M, Schaffer P, Raverdy N, et al. Incidence
du mesotheliome dans les registres des can-
cers Fran,ais. Estimation France entiere. Bull
Epidemiol Hebd 12:57-58 (1996).
45. lwatsubo Y, Pairon JC, Archambault C,
Chammong's S, Bignon J, Broxhard P. Pleural
mesothelioma: descriptive analysis based on a
case-control study and mortality data in lle-de-
France 1987-1990. Am J Ind Med 26:77-88
(1994).
46. Le Bacle C, Bouchami R, Goulfier C. Silicose: Ia sit-
uation en France dans les annees 90. Documents
Medecin Travail INRS63:159-165(1995).
47. Caisse Autonome Nationale Securite Secours
Miniere (CANSSM). Rapport de Gestion 1997:
statistiques du Regime Special de Securite
Sociale dans les Mines. Paris, 1994.
48. Leclerc A, Martinez-Cortes M, Gerin M, Luce D,
Brugbre J. Sinonasal cancer and wood dust
exposure: results form a case-control study. Am
J Epidemiol 140:340-349 (1994).
49. Luce D, Gerin M, Leclerc A, Morcet JF, Brugere
J, Goldberg M. Sinonasal cancer and occupa-
tional exposure to formaldehyde and other sub-
stances. Int J Cancer. 53:224-231 (1993).
50. Directive du Conseil 90/394/EEC du 28 Juin
1990 mod. concernant la protection des tra-
vailleurs contre les risques lies a 'exposition a
des agents cancerigenes au travail. J.O.C.E. n°
L 196, 26 Juillet 1990.
51. Directive du Conseil 67/548/EEC du 27 Juin
1967 mod. concernant le rapprochement des
dispositions legislatives, reglementaires et
administratives relatives a la classification,
'emballage et l'dtiquetage des substances
dangeureuses. J.0.C.E. n° 196, 16 AoOt 1967.
52. Cahier de Notes Documentaires, INRS En partic-
ulier ND 2063-169-97: Produits chimiques
cancerogenes, mutagenes, toxiques pour la repro-
duction - classification reglementaire. Cahiers
Notes Documentaires 169:547-573(1997).
53. Oudiz A, Moatti JP. Les valeurs limites d'expo-
sition aux cancerogbnes professionnels: point
actuel et perspectives. INSERM U 240
Preventique 26:28-33 (1989)
54. Decret n° 92-1261 du 3 Decembre 1992 relatif
a la prevention du risque chimique et modifiant
la section V du chapitre ler du titre IlIl du livre 11
du Code du Travail. J.O. 5 Decembre 1992.
55. Decret n° 89-593 du 28 Aout 1989 reglementant
la production et lutilisation de certaines sub-
stances dangeureuses. J.O. du 30 AoOt 1989.
56. Directive du Conseil 88/364/CEE du 9 Juin 1988
concernant la protection des travailleurs par
linterdiction de certains agents specifiques
et/ou de certaines activites. J.0.C.E. n° L 179,
9 Juillet 1988.
57. Comite Fran,ais d'Education pour la Sante. Les
Maladies Professionnelles-Guide d'Acces aux
Tableaux. Paris, 1996.
58. Brugere J, Th6baud-Mony A, Pezerat H, Cassou
B. Cancers professionnels: connaissance, repara-
tion et prevention. Bull Cancer 81:14-21 (1994).
59. Martinet Y. La Legislation des maladies d'origine
professionnelle et leur reparation. In: Les
Maladies Respiratoires d'Origine Professionnelle
(Martinet Y, Anthoine D, eds). Paris:Masson,
1995;229-236.
60. Martinet Y. Le cancer bronchique. In: Les
Maladies Respiratoires d'Origine Professionnelle
(Martinet Y, Anthoine D, eds). Paris:Masson,
1995;138-147.
61. Loi n° 93-121 du 27 Janvier 1993 portant diverses
mesures d'ordre social. J.O. 30 Janvier 1993.
62. Th6baud-Mony A. de la Connaissance a la
Reconnaissance des Maladies Professionnelles
en France; Rapport de Synthese: ISIS - INSERM
U 292. Paris:Les Editions de l'INSERM, 1990.
63. Sancho-Garnier H, Benhamou S. Les cancers
d'origine professionnelle - Edition Techniques
Encyclopedie Medico-Chirurgicale Intoxications
Pathologie du Travail. 16532 A10, Encyclopedie
Medico-Chirurgicale, Paris: 1990.
64. Direction des Relations du Travail. Ministere
du Travail et des Affaires Sociales: Conditions
de Travail - Bilans 1994 et 1995, Paris:La
Documentation Fran,aise, 1995, 1996.
65. Boffetta P, Kogevinas M. Occupational cancer
in Europe. Med Lavo86(3):236-262 (1995).
252 Environmental Health Perspectives * Vol 107, Supplement 2 * May 999